EZH2 and B-cell chronic lymphocytic leukemia: Additionally, EZH2 has actions that induce the PI3K/AKT pathway in clinically aggressive chronic lymphocytic leukemia [46], and it modulates the cardioprotective effects of mesenchymal-stem-cell-secreted exosomes via HMGA2-mediated PI3K/AKT signaling [19].